Search Results - "Eketjall, Susanna"
-
1
High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus
Published in Arthritis research & therapy (29-04-2019)“…Interferons (IFNs) are considered to be key molecules in the pathogenesis of systemic lupus erythematosus (SLE). We measured levels of type I, II and III IFNs…”
Get full text
Journal Article -
2
Sjögren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State
Published in Journal of rheumatology (01-06-2020)“…An often-neglected subset of patients with systemic lupus erythematosus (SLE) is those with secondary Sjögren syndrome (SLE-sSS). Further, primary SS overlaps…”
Get full text
Journal Article -
3
TREM2 shedding by cleavage at the H157‐S158 bond is accelerated for the Alzheimer's disease‐associated H157Y variant
Published in EMBO molecular medicine (01-10-2017)“…We have characterised the proteolytic cleavage events responsible for the shedding of triggering receptor expressed on myeloid cells 2 (TREM2) from primary…”
Get full text
Journal Article -
4
Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus
Published in Journal of proteome research (01-03-2019)“…The aim of this study was to evaluate how the cytokine profiles differed between autoantibody based subgroups of systemic lupus erythematosus (SLE). SLE is a…”
Get full text
Journal Article -
5
Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease
Published in The Journal of biological chemistry (30-11-2012)“…β-Site amyloid precursor protein cleaving enzyme1 (BACE1) is one of the key enzymes involved in the processing of the amyloid precursor protein (APP) and…”
Get full text
Journal Article -
6
Microparticles in the blood of patients with SLE: Size, content of mitochondria and role in circulating immune complexes
Published in Journal of autoimmunity (01-08-2019)“…Microparticles (MPs) are small extracellular vesicles released from apoptotic or activated cells through a blebbing process. MPs express surface molecules from…”
Get full text
Journal Article -
7
AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
Published in Journal of Alzheimer's disease (01-01-2016)“…A growing body of pathological, biomarker, genetic, and mechanistic data suggests that amyloid accumulation, as a result of changes in production, processing,…”
Get more information
Journal Article -
8
Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease
Published in Cardiovascular research (04-07-2023)“…Abstract Aims The vascular endothelial growth factor (VEGF) family is involved in pathophysiological mechanisms underlying cardiovascular (CV) diseases. The…”
Get full text
Journal Article -
9
Development of a highly sensitive liquid chromatography - mass spectrometry method to quantify plasma leukotriene E 4 and demonstrate pharmacological suppression of endogenous 5-LO pathway activity in man
Published in Prostaglandins & other lipid mediators (01-10-2020)“…Low basal endogenous concentrations (< 20 pg/mL) of the 5-lipoxygenase (5-LO) pathway biomarker leukotriene E (LTE ) in human plasma present a significant…”
Get full text
Journal Article -
10
Toward β‑Secretase‑1 Inhibitors with Improved Isoform Selectivity
Published in Journal of medicinal chemistry (26-04-2018)“…BACE1 is responsible for the first step in APP proteolysis, leading to toxic Aβ production, and has been indicated to play a key role in the pathogenesis of…”
Get full text
Journal Article -
11
New Aminoimidazoles as β‑Secretase (BACE-1) Inhibitors Showing Amyloid‑β (Aβ) Lowering in Brain
Published in Journal of medicinal chemistry (08-11-2012)“…Amino-2H-imidazoles are described as a new class of BACE-1 inhibitors for the treatment of Alzheimer’s disease. Synthetic methods, crystal structures, and…”
Get full text
Journal Article -
12
Design and Synthesis of β‑Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors with in Vivo Brain Reduction of β‑Amyloid Peptides
Published in Journal of medicinal chemistry (08-11-2012)“…The evaluation of a series of aminoisoindoles as β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and the discovery of a clinical…”
Get full text
Journal Article -
13
AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease
Published in Journal of Alzheimer's disease (01-01-2017)“…AZD3293 (LY3314814) is a promising new potentially disease-modifying BACE1 (β-secretase) inhibitor in Phase III clinical development for the treatment of…”
Get more information
Journal Article -
14
Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
Published in Annals of the rheumatic diseases (01-07-2018)“…Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) have increased risk of cardiovascular disease (CVD). We investigated whether…”
Get more information
Journal Article -
15
Highly sensitive and specific LC–MS/MS method to determine endogenous leukotriene B4 levels in human plasma
Published in Bioanalysis (01-06-2019)“…To develop a high sensitivity and specific analytical method to measure endogenous levels of leukotriene B4 (LTB ) in human plasma. LC–MS/MS and ELISA. An…”
Get full text
Journal Article -
16
MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non‐clinical species and Alzheimer's disease patients
Published in Alzheimer's & dementia (01-11-2024)“…INTRODUCTION Small molecules and antibodies are being developed to lower amyloid beta (Aβ) peptides. METHODS We describe MEDI1814, a fully human high‐affinity…”
Get full text
Journal Article -
17
TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
Published in Lupus science & medicine (01-01-2018)“…ObjectivesComposite criteria/indices are presently used to diagnose and monitor patients with systemic lupus erythematosus (SLE). Biomarkers for these purposes…”
Get full text
Journal Article -
18
Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β‐amyloid levels in the CNS
Published in Journal of neurochemistry (01-02-2015)“…Aggregation of amyloid beta (Aβ) peptides and the subsequent neural plaque formation is a central aspect of Alzheimer's disease. Various strategies to reduce…”
Get full text
Journal Article -
19
Determining myeloperoxidase activity and protein concentration in a single assay: Utility in biomarker and therapeutic studies
Published in Journal of immunological methods (01-10-2017)“…Myeloperoxidase (MPO) is predominantly expressed by neutrophils and is an important enzyme used by the immune system for the neutralisation of bacteria and…”
Get full text
Journal Article -
20
Kynurenine pathway is altered in patients with SLE and associated with severe fatigue
Published in Lupus science & medicine (01-01-2018)“…ObjectiveFatigue has been reported as the most disturbing symptom in a majority of patients with SLE. Depression is common and often severe. Together these…”
Get full text
Journal Article